Viracta Therapeutics Stock (NASDAQ:VIRX)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.19

52W Range

$0.18 - $1.31

50D Avg

$0.23

200D Avg

$0.58

Market Cap

$7.88M

Avg Vol (3M)

$1.16M

Beta

0.28

Div Yield

-

VIRX Company Profile


Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

40

IPO Date

Sep 27, 2005

Website

VIRX Performance


VIRX Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-50.69M$-50.59M$62.50M
Net Income$-51.06M$-49.77M$-203.06M
EBITDA$-50.69M$-50.59M$62.68M
Basic EPS-$-1.32$-6.37
Diluted EPS-$-1.32$-6.37

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
EYPTEyePoint Pharmaceuticals, Inc.
BMEABiomea Fusion, Inc.
TNYATenaya Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
ALXOALX Oncology Holdings Inc.
SQZSQZ Biotechnologies Company
IGMSIGM Biosciences, Inc.
RLYBRallybio Corporation
TERNTerns Pharmaceuticals, Inc.
CABACabaletta Bio, Inc.
INZYInozyme Pharma, Inc.
GLUEMonte Rosa Therapeutics, Inc.
VINCVincerx Pharma, Inc.
TARAProtara Therapeutics, Inc.
TRVITrevi Therapeutics, Inc.
LPTXLeap Therapeutics, Inc.
BCYCBicycle Therapeutics plc
LYRALyra Therapeutics, Inc.